AbbVie Advances Venetoclax Into Rare Blood Cancers With New Phase 2 Study
Abbvie (ABBV) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AbbVie is running a Phase 2 study in Japan to test venetoclax in adults with relapsed or refractory Waldenström macroglobulinemia or lymphoplasmacytic lymphoma, two rare blood cancers. The goal is to see how much the disease activity changes with this oral drug and whether it offers a new option where current treatments are limited.
The study tests venetoclax, an oral cancer medicine designed to trigger cancer cell death by blocking a key survival pathway. It is already used in other blood cancers, and here AbbVie aims to show it can help this small but underserved patient group as a stand‑alone treatment.
The trial uses a single treatment group, so every participant receives venetoclax with no placebo or comparison arm. There is no blinding, meaning doctors and patients know they are getting the study drug, and the main purpose is direct treatment rather than prevention or diagnosis.
The study started after first submission on 28 January 2026, and is planned to run for about 28 months, with a primary completion date likely in late 2028. The most recent protocol update was filed on 2 March 2026, signaling that the design and operational plans are current.
For investors, this update reinforces AbbVie’s push to expand venetoclax into niche blood cancers, which could support durable revenue from oncology beyond current indications. While the patient pool is small and near‑term sales impact modest, positive data could strengthen ABBV’s franchise versus rivals in hematology and add to the company’s innovation story.
The study remains active and under way, with ongoing updates and full protocol details available on the ClinicalTrials.gov portal.
To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.
